Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Riboflavin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.73 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 7/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.85 |
| ▸ | USP2 | O75604 | 4/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.85 |
| ▸ | HAT1 | O14929 | 4/20 | 0.85 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.85 |
| ▸ | HTT | P42858 | 4/20 | 0.85 |
| ▸ | RECQL | P46063 | 3/20 | 0.85 |
| ▸ | CASP7 | P55210 | 3/20 | 0.85 |
| ▸ | MAPT | P10636 | 3/20 | 0.85 |
| ▸ | CASP1 | P29466 | 2/20 | 0.85 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.85 |
| ▸ | TST | Q16762 | 2/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | HBB | P68871 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboflavin SCHEMBL535031 | 0.99 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL50154 | 0.99 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL27866166 | 0.99 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL367681 | 0.97 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL1085508 | 0.97 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL296802 | 0.96 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL21805317 | 0.96 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL618997 | 0.96 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL20474794 | 0.95 | MEN1 (0.90) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL2241206 | 0.94 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2663281-B1 | CORNEAL DELIVERY OF CROSS-LINKING AGENTS BY IONTOPHORESIS FOR THE TREATMENT OF KERATOCONUS AND RELATED OPHTHALMIC COMPOSITIONS | SOOFT ITALIA S P A (IT) | 2016-08-10 | — | — | EP | claimed |
| US-20130310732-A1 | CORNEAL DELIVERY OF CROSS-LINKING AGENTS BY IONTOPHORESIS FOR THE TREATMENT OF KERATOCONUS AND RELATED OPHTHALMIC COMPOSITIONS | SOOFT ITALIA SPA (IT) | 2013-11-21 | — | — | US | claimed |
| EP-2663335-A1 | A COMPOSITION FOR THE REGENERATION OF ATROPHIC TISSUES | Medestea Internazionale S.p.A. (IT) | 2013-11-20 | — | — | EP | claimed |
| US-20130287757-A1 | COMPOSITION FOR THE REGENERATION OF ATROPHIC TISSUES | MEDESTEA INTERNAZIONALE S.P.A. (IT) | 2013-10-31 | — | — | US | claimed |
| WO-2012095702-A1 | A COMPOSITION FOR THE REGENERATION OF ATROPHIC TISSUES | MEDESTEA INTERNAZIONALE S.P.A. (IT) | 2012-07-19 | — | — | WO | claimed |
| EP-2663281-B1 | CORNEAL DELIVERY OF CROSS-LINKING AGENTS BY IONTOPHORESIS FOR THE TREATMENT OF KERATOCONUS AND RELATED OPHTHALMIC COMPOSITIONS | SOOFT ITALIA S P A (IT) | 2016-08-10 | — | — | EP | disclosed |
| US-20140066439-A1 | OSTEOCLAST ACTIVITY | Katholieke Universiteit Leuen, K.U.Leuven R&D (BE) | 2014-03-06 | — | — | US | disclosed |
| EP-2323642-B1 | Use of EDTA+tromethamine or of photoenhancers, associated to riboflavin for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders | SOOFT ITALIA S P A (IT) | 2014-02-19 | — | — | EP | disclosed |
| EP-2663335-A1 | A COMPOSITION FOR THE REGENERATION OF ATROPHIC TISSUES | Medestea Internazionale S.p.A. (IT) | 2013-11-20 | — | — | EP | disclosed |
| US-20130287757-A1 | COMPOSITION FOR THE REGENERATION OF ATROPHIC TISSUES | MEDESTEA INTERNAZIONALE S.P.A. (IT) | 2013-10-31 | — | — | US | disclosed |
| EP-2637652-A2 | OSTEOCLAST ACTIVITY | Katholieke Universiteit Leuven (BE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012095702-A1 | A COMPOSITION FOR THE REGENERATION OF ATROPHIC TISSUES | MEDESTEA INTERNAZIONALE S.P.A. (IT) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012061907-A2 | OSTEOCLAST ACTIVITY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120015901-A1 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-01-19 | — | — | US | disclosed |
| EP-2398472-A2 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS WITH A POLYAMINE (E.G. SPERMINE, SPERMIDINE) | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2011-12-28 | — | — | EP | disclosed |
| US-20110152219-A1 | USE OF ENHANCERS, POSSIBLY ASSOCIATED TO RIBOFLAVIN, AS WELL AS CORRESPONDING OPHTHALMIC COMPOSITIONS FOR CORNEAL CROSS-LINKING IN THE TREATMENT OF THE KERATOCONUS OR OF OTHER CORNEAL ECTASIC DISORDERS | SOOFT ITALIA SPA (IT) | 2011-06-23 | — | — | US | disclosed |
| WO-2010081862-A2 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010013191-A2 | COSMETIC COMPOSITION AND PROCESS FOR REGROWTH OF INTEGUMENTARY SYSTEM | GENNERO LUISA (IT) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010013190-A2 | COMPOSITION FOR HYPERTROPHIC TISSUE REGENERATION, PRODUCTS AND USES THEREOF | GENNERO LUISA (IT) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015901-A1 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | BECN1, SQSTM1, ATG7 | ADRB2 4258/4885ADRA1A 3952/4885MEN1 3687/4885 |
| US-20140066439-A1 | OSTEOCLAST ACTIVITY | CTSA, SQSTM1, BECN1 | ADRB2 1658/4885ADRA1A 1768/4885MEN1 3235/4885 |
| US-20110152219-A1 | USE OF ENHANCERS, POSSIBLY ASSOCIATED TO RIBOFLAVIN, AS WELL AS CORRESPONDING OPHTHALMIC COMPOSITIONS FOR CORNEAL CROSS-LINKING IN THE TREATMENT OF THE KERATOCONUS OR OF OTHER CORNEAL ECTASIC DISORDERS | VKORC1L1, VKORC1, ENPP1 | ADRB2 2692/4885ADRA1A 3032/4885MEN1 4624/4885 |
| US-20130287757-A1 | COMPOSITION FOR THE REGENERATION OF ATROPHIC TISSUES | CUTA, UNG, MMP1 | ADRB2 814/4885ADRA1A 1648/4885MEN1 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.